11:07 AM EST, 02/03/2025 (MT Newswires) -- Natera ( NTRA ) on Monday announced a new policy for commercial coverage of its cell-free DNA fetal RhD noninvasive prenatal test in the US.

Under the new policy, coverage of fetal RhD testing will be available when a pregnancy may be facing risk for alloimmunization, when paternal antigen typing is unavailable or heterozygous, and if a patient declines amniocentesis or it is not recommended for the pregnancy, effective January, the company said.

Natera ( NTRA ) said fetal RhD noninvasive prenatal test is offered through its women's health suite of products and can be carried out as early as nine weeks gestation.

Price: 177.74, Change: +0.82, Percent Change: +0.46